BCMLT
BCRX icon

Beacon Capital Management LLC (Tennessee)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,170
Closed -$13.4K – 950
2022
Q4 		$13.4K Hold
1,170
– – ﹤0.01% 444
2022
Q3 		$12K Hold
1,170
– – ﹤0.01% 436
2022
Q2 		$19K Hold
1,170
– – ﹤0.01% 408
2022
Q1 		$19K Buy
+1,170
New +$18.8K ﹤0.01% 408

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s BCRX Position: Q1 2023 in Review

Beacon Capital Management LLC (Tennessee) sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 1,170 shares — an estimated $13.4K sold.

Beacon Capital Management LLC (Tennessee) first reported a position in BCRX in Q1 2022 and held it in 4 quarters. The position peaked at $19K in Q2 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

  • Beacon Capital Management LLC (Tennessee) reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Beacon Capital Management LLC (Tennessee) sold 1,170 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $13.4K.
  • Beacon Capital Management LLC (Tennessee) first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Beacon Capital Management LLC (Tennessee)'s BioCryst Pharmaceuticals position peaked at $19K in Q2 2022.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q1 2023, filed 20 Apr 2023.